keyword
MENU ▼
Read by QxMD icon Read
search

Lentigo maligna

keyword
https://www.readbyqxmd.com/read/28802488/characterization-of-surgical-procedures-in-the-spanish-mohs-surgery-registry-regesmohs-for-2013-2015
#1
E de Eusebio Murillo, A Martín Fuentes, V Ruiz-Salas, J R Garcés, R Miñano Medrano, J L López-Estebaranz, T Alonso-Alonso, M Á Rodríguez-Prieto, Y Delgado Jiménez, V Morales, P Redondo Bellón, E Manubens-Mercadé, O Sanmartín-Jiménez, C Guillén Barona, R Cabeza, N Cano, A Toll-Abelló, R Navarro Tejedor, J L Artola Igarza, I Allende Markixana, A Alfaro Rubio, C Ciudad Blanco, H Vázquez-Veiga, L Barchino Ortiz, M A Descalzo, I García-Doval
INTRODUCTION: The Spanish Mohs Surgery Registry is used to collect data on the use and outcomes of Mohs micrographic surgery (MMS) in Spain. The aim of this study was to describe perioperative and intraoperative data recorded for MMS procedures performed between July 2013 (when the registry started) and January 2016. MATERIAL AND METHODS: Prospective cohort study of data from 18 hospitals. The data collected included type of anesthesia, surgical technique, hospital admission, number of Mohs stages, management of preoperative risk factors, additional treatments, previous treatments, type of tumor, operating time, and complications...
August 9, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28737763/melanoma-subtypes-demonstrate-distinct-pd-l1-expression-profiles
#2
Genevieve J Kaunitz, Tricia R Cottrell, Mohammed Lilo, Valliammai Muthappan, Jessica Esandrio, Sneha Berry, Haiying Xu, Aleksandra Ogurtsova, Robert A Anders, Alexander H Fischer, Stefan Kraft, Meg R Gerstenblith, Cheryl L Thompson, Kord Honda, Jonathan D Cuda, Charles G Eberhart, James T Handa, Evan J Lipson, Janis M Taube
PD-L1 expression in the tumor immune microenvironment is recognized as both a prognostic and predictive biomarker in patients with cutaneous melanoma, a finding closely related to its adaptive (IFN-γ-mediated) mechanism of expression. Approximately 35% of cutaneous melanomas express PD-L1, however, the expression patterns, levels, and prevalence in rarer melanoma subtypes are not well described. We performed immunohistochemistry for PD-L1 and CD8 on 200 formalin-fixed paraffin-embedded specimens from patients with acral (n=16), mucosal (n=36), uveal (n=103), and chronic sun-damaged (CSD) (n=45) melanomas (24 lentigo maligna, 13 'mixed' desmoplastic, and 8 'pure' desmoplastic melanomas)...
July 24, 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/28724272/patients-characteristics-histopathological-findings-and-tumor-stage-in-different-types-of-malignant-melanoma-a-retrospective-multicenter-study
#3
Ali-Mohammad Farahmand, Amir-Hoshang Ehsani, Mojtaba Mirzaei, Maryam Mohsenian, Alireza Ghanadan
Cutaneous malignant melanoma (CMM) is currently the most fatal of skin cancers accounting for 50000 deaths annually. Five distinct melanomas are described histopathologically: superficial spreading, lentigo maligna, nodular, acral lentiginous and mucosal melanoma. The aim of this study was to investigate the characteristics of patients with various types of malignant melanoma and evaluate histopathological findings. In this retrospective study, we obtained our data from the records of 111 patients with melanoma...
May 2017: Acta Medica Iranica
https://www.readbyqxmd.com/read/28705516/dermoscopy-of-pigmented-actinic-keratosis-of-the-face-a-study-of-232-cases
#4
A Kelati, H Baybay, E Moscarella, G Argenziano, S Gallouj, F Z Mernissi
The diagnosis of pigmented actinic keratosis (PAK) is often challenging because of overlapping features with lentigo maligna. OBJECTIVE: To investigate dermoscopic patterns of PAK according to their different evolutionary stages, and to correlate the pattern with clinical characteristics of the patients. METHODS: Descriptive and analytical study of 232 PAK. Dermoscopic patterns were divided into two categories: the follicule surroundings' abnormalities (FSA) and follicular keratosis' abnormalities (FKA)...
July 11, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28685596/amelanotic-lentigo-maligna-melanoma-mohs-surgery-as-the-definitive-treatment-of-an-invisible-tumour
#5
Marisa Grace Ponzo, Richard Ian Crawford, Irèn Kossintseva
Amelanotic lentigo maligna melanoma represents <2% of melanomas. Diagnosis is delayed owing to the lack of lesion pigmentation and advanced disease at presentation. Excision with appropriate margins is the treatment standard, but the starting point for such margins is often unclear. We describe 2 patients with amelanotic melanoma treated by Mohs micrographic surgery (MMS) that would not have been cleared by wide local excision alone and provide an extensive review of the literature. Both patients presented with histologic diagnoses of malignant melanoma, one with a barely perceptible biopsy site scar on the left infraorbital cheek/lower eyelid (Breslow 1...
July 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28670076/acute-exacerbation-of-myasthenia-gravis-with-topical-imiquimod-use
#6
Saadeddine Saad, Bobbak Mansouri, Chad Housewright
Imiquimod activates the immune system when applied to a local area. We report a patient with a history of well-controlled myasthenia gravis who was prescribed imiquimod for lentigo maligna. Treatment was halted after 2 weeks when the patient reported itching and irritating sensations in his throat, consistent with previous myasthenia exacerbations. The symptoms improved once imiquimod use was discontinued. We advise clinicians to be cautious when prescribing imiquimod to a patient with a history of myasthenia gravis...
July 2017: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/28632796/handheld-reflectance-confocal-microscopy-to-aid-in-the-management-of-complex-facial-lentigo-maligna
#7
Brian P Hibler, Oriol Yélamos, Miguel Cordova, Heidy Sierra, Milind Rajadhyaksha, Kishwer S Nehal, Anthony M Rossi
Diagnosis and management of lentigo maligna (LM) and LM melanoma (LMM) is challenging. Novel noninvasive imaging technologies such as reflectance confocal microscopy (RCM) have advanced the ability to better diagnose and monitor challenging lesions. In addition, the new handheld RCM (HRCM) together with the use of videomosaics has allowed an accurate evaluation of large lesions in concave/convex areas of the body (eg, the face). Herein, we review the impact of HRCM in the detection, treatment decision-making, and monitoring of 5 cases of complex facial LM/LMM...
May 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28630590/analysis-of-prognostic-factors-for-melanoma-patients
#8
Andrė Lideikaitė, Julija Mozūraitienė, Simona Letautienė
Introduction. Melanoma is the most dangerous form of skin cancer. Morbidity from melanoma is increasing every year. Previous studies have revealed that there are some demographic and clinical factors having effect on melanoma survival prognosis. Aim of the study. Purpose of our study was to assess melanoma survival depending on prognostic factors, such as age, sex, stage, depth, histology and anatomical site. Materials and methods. We investigated melanoma-specific survival up to 10 years in 85 primary cases of melanoma from diagnosis at the National Cancer Institute in 2006...
2017: Acta medica Lituanica
https://www.readbyqxmd.com/read/28628689/aggressive-skin-cancers-occurring-in-patients-treated-with-the-janus-kinase-inhibitor-ruxolitinib
#9
Adam B Blechman, Christine E Cabell, Christine H Weinberger, Anna Duckworth, Justin J Leitenberger, Fiona O Zwald, Mark A Russell
<p>The Food and Drug Administration approved Ruxolitinib in 2011 for the treatment of primary myelofibrosis. Five-year safety data showed a higher incidence of skin cancer in patients treated with Ruxolitinib compared to best available therapy for myelofibrosis. This report presents a series of five patients with history of myelofibrosis treated with Ruxolitinib who subsequently developed numerous skin cancers with aggressive biological behavior. Each patient in this report was treated by a Mohs surgeon affiliated with an academic institution...
May 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28589538/lentigo-maligna-of-the-face-a-quantitative-simple-method-to-identify-individual-patient-risk-probability-on-dermoscopy
#10
Anna Carbone, Angela Ferrari, Giovanni Paolino, Pierluigi Buccini, Paola De Simone, Laura Eibenschutz, Paolo Piemonte, Vitaliano Silipo, Isabella Sperduti, Caterina Catricalà, Pasquale Frascione
BACKGROUND/OBJECTIVES: The clinical and dermoscopic differential diagnosis of flat pigmented facial lesions represents a great challenge for the clinicians. Our aim was to report a quantitative method based on dermoscopic features to better classify pigmented facial lesions. METHODS: This is a retrospective case-series study that analysed the dermoscopic features of 582 pigmented facial lesions. RESULTS: The individual patient probability of lentigo maligna (LM) was predicted by a multivariate model, with an accuracy of 0...
June 7, 2017: Australasian Journal of Dermatology
https://www.readbyqxmd.com/read/28564685/histopathologic-and-immunohistochemical-correlates-of-confocal-descriptors-in-pigmented-facial-macules-on-photodamaged-skin
#11
Ignacio Gómez-Martín, Sara Moreno, Evelyn Andrades-López, Inma Hernández-Muñoz, Fernando Gallardo, Carlos Barranco, Ramon M Pujol, Sonia Segura
Importance: Pigmented facial macules on photodamaged skin are a clinical, dermoscopic, and histopathologic challenge. Objectives: To clinically and dermoscopically characterize, by means of reflectance confocal microscopy (RCM), ambiguous pigmented facial macules and establish a correlation between RCM, histopathologic, and immunohistochemical findings. Design, Setting, and Participants: A prospective study of ambiguous pigmented facial macules on photodamaged skin was conducted in a tertiary referral center for dermatology between January 1, 2009, and December 31, 2015...
August 1, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28556434/integration-of-reflectance-confocal-microscopy-into-clinical-practice-for-the-management-of-lentigo-maligna
#12
F R Ali, E E Craythorne
No abstract text is available yet for this article.
May 29, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28555933/lentigo-maligna-melanoma-with-a-history-of-cosmetic-treatment-prevalence-surgical-outcomes-and-considerations
#13
Brian P Hibler, Karen L Connolly, Erica H Lee, Anthony M Rossi, Kishwer S Nehal
INTRODUCTION: Lentigo maligna (LM) is melanoma in situ on sun-damaged skin and presents diagnostic challenges due to overlapping features with benign pigmented lesions. Cosmetic treatments may be inadvertently performed on LM. The aim of this study is to estimate the prevalence of LM with prior cosmetic treatment, and evaluate surgical outcomes. STUDY DESIGN AND METHODS: Retrospective review of biopsy-proven LM presenting over a 10-year-period (2006-2015). Prior cosmetic treatment and biopsies were recorded...
May 29, 2017: Lasers in Surgery and Medicine
https://www.readbyqxmd.com/read/28504388/challenges-of-treating-melanoma-in%C3%A2-situ-lentigo-maligna-type-is-pathological-clearance-the-gold-standard
#14
S M Swetter
No abstract text is available yet for this article.
May 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28436290/topography-of-protein-kinase-c-%C3%AE-ii-in-benign-and-malignant-melanocytic-lesions
#15
Konstanin Krasagakis, Eleftheria Tsentelierou, Gregory Chlouverakis, Efstathios N Stathopoulos
BACKGROUND: Protein kinase C βII promotes melanogenesis and affects proliferation of melanocytic cells but is frequently absent or decreased in melanoma cells in vitro. OBJECTIVE: To investigate PKC-βII expression and spatial distribution within a lesion in various benign and malignant melanocytic proliferations. METHODS: Expression of PKC-βII was semiquantitatively assessed in the various existing compartments (intraepidermal [not nested], junctional [nested], and dermal) of benign (n = 43) and malignant (n = 28) melanocytic lesions by immunohistochemistry...
April 1, 2017: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28436025/melanoma-in%C3%A2-situ-of-lentigo-maligna-type-in-a-young-woman
#16
Matthew F Helm, Michael J Bax, David J Augenblick, Catherine G Chung
No abstract text is available yet for this article.
April 23, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28403068/malignant-melanoma-in-african-americans-a-population-based-clinical-outcomes-study-involving-1106-african-american-patients-from-the-surveillance-epidemiology-and-end-result-seer-database-1988-2011
#17
Krishnaraj Mahendraraj, Komal Sidhu, Christine S M Lau, Georgia J McRoy, Ronald S Chamberlain, Franz O Smith
Malignant melanoma accounts for 75% of all skin cancer deaths and is potentially curable if identified early. Although melanoma is rare in African-Americans (AA), it is associated with a worse prognosis than in Caucasians. This study examines the demographic, pathologic, and clinical factors impacting AA melanoma outcomes.Data for 1106 AA and 212,721 Caucasian cutaneous melanoma patients were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (1988-2011). Data were grouped on the basis of histological subtypes: "Superficial Spreading" (SS), "Nodular" (NM), "Lentigo Maligna" (LM), "Acral Lentiginous" (AL), and "Not otherwise specified" (NOS)...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28369728/imiquimod-treatment-for-lentigo-maligna-limit-1-trial
#18
LETTER
N G Maher, P Guitera
No abstract text is available yet for this article.
March 29, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28348944/tumoral-melanosis-associated-with-pembrolizumab-treated-metastatic-melanoma
#19
Omar Bari, Philip R Cohen
Tumoral melanosis is a form of completely regressed melanoma that usually presents as darkly pigmented lesions suspicious for malignant melanoma. Histology reveals dense dermal and subcutaneous infiltration of melanophages. Pembrolizumab is an antibody directed against programmed death receptor-1 (PD1) and is frontline treatment for advanced melanoma. An 81-year-old man with metastatic melanoma treated with pembrolizumab who developed tumoral melanosis at previous sites of metastases is described. The PubMed database was searched with the key words: antibody, immunotherapy, melanoma, melanosis, metastasis, pembrolizumab, and tumoral...
February 13, 2017: Curēus
https://www.readbyqxmd.com/read/28346250/reconstruction-of-combined-upper-and-lower-eyelid-defects-in-a-patient-with-lentigo-maligna
#20
Ana Martínez-Palmer, Marta Calsina-Prat, Nerea Ormaechea, Agustí Toll
No abstract text is available yet for this article.
May 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
keyword
keyword
20475
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"